目的 探討川芎嗪注射液聯(lián)合拉貝洛爾治療妊娠期高血壓的臨床效果。方法 選取興寧市婦幼保健院2015年3月-2016年12月收治的妊娠期高血壓患者98例，隨機分為對照組與治療組，每組各49例。對照組患者靜脈滴注鹽酸拉貝洛爾注射液，50 mg加入5%葡萄糖溶液250 mL中，1次/d。治療組患者在對照組的基礎(chǔ)上靜脈滴注鹽酸川芎嗪注射液，120 mg加入5%葡萄糖溶液250 mL，1次/d。兩組患者均治療10 d。評價兩組患者臨床療效，同時比較治療前后兩組患者血壓、血漿黏度、24 h蛋白尿定量、尿素氮（BUN）、尿微量清蛋白（MA）、超敏C反應蛋白（hs-CRP）和同型半胱氨酸（Hcy）水平變化情況。結(jié)果 治療后，對照組和治療組總有效率分別為79.59%、93.88%，兩組比較差異具有統(tǒng)計學意義（P<0.05）。治療后，兩組患者舒張壓和收縮壓均明顯下降（P<0.05）；且治療組患者的血壓水平明顯優(yōu)于對照組（P<0.05）。治療后，兩組患者血漿黏度、24 h蛋白尿定量和MA水平均明顯降低（P<0.05）；且治療組患者上述觀察指標水平明顯低于對照組（P<0.05）。治療后，兩組患者血清hs-CRP和Hcy水平均顯著降低（P<0.05）；且治療組患者hs-CRP與Hcy水平顯著低于對照組（P<0.05）。結(jié)論 川芎嗪聯(lián)合拉貝洛爾治療妊娠期高血壓療效顯著，且具有較高的安全性，具有一定的臨床推廣應用價值。

Objective To investigate the clinical efficacy and safety of Ligustrazine Hydrochloride Injection combined with labetalol in treatment of gestational hypertension. Methods Patients (98 cases) with gestational hypertension in Xingning Maternal and Child Health Care Hospital from March 2015 to December 2016 were randomly divided into control and treatment groups, and each group had 49 cases. Patients in the control group were iv administered with Labetalol Hydrochloride Injection, 50 mg added into 5% glucose injection 250 mL, once daily. Patients in the treatment group were iv administered with Ligustrazine Hydrochloride Injection on the basis of the control group, 120 mg added into 5% glucose injection 250 mL, once daily. Patients in two groups were treated for 10 d. After treatment, the clinical efficacy was evaluated, and the changes of blood pressure, plasma viscosity, 24 h urinary protein, BUN, MA, hs-CRP and Hcy levels in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control and treatment groups were 79.59% and 93.88%, respectively, and there were differences between two groups (P<0.05). After treatment, the diastolic and systolic blood pressure in two groups was significantly decreased (P<0.05). And the blood pressure level in the treatment group was obviously better than that in the control group (P<0.05). After treatment, the plasma viscosity, 24 h urinary protein, and MA levels in two groups were significantly decreased (P<0.05). And these index levels in the treatment group were obviously lower than those in the control group (P<0.05). After treatment, hs-CRP and Hcy levels in two groups were significantly decreased (P<0.05). And the hs-CRP and Hcy levels in the treatment group were obviously lower than those in the control group (P<0.05). Conclusion Ligustrazine Hydrochloride Injection combined with labetalol has significant curative effect in treatment of gestational hypertension with high security, which has a certain clinical application value.